Upon Food and Drug Administration (FDA) approval, the Association for the Advancement of Blood & Biotherapies (AABB) has added lenacapavir (Yeztugo, Gilead) to their AABB Medication Deferral List (MDL), version 4.0, according to a release.
Lenacapavir is a “long-acting injectable pre-exposure prophylaxis (PrEP) medication.” Furthermore, AABB’s Transfusion Transmitted Diseases (TTD) Committee decided to “recommended maintaining the current Donor History Questionnaire (DHQ) v4.0 and the associated deferrals, and adding lenacapavir to the MDL v4.0 with a two-year deferral period.”
Additionally, “the update to the MDL should be implemented as defined in the blood collection establishment standard operating procedures and as soon as reasonably possible.” Licensed blood establishments “are required to report this minor change and its implementation date in their next annual report,” according to 21 CFR 601.12(d).
